Caris Life Sciences closed growth capital funding round of $168 million
Summary
This raise will help us bring our market-leading science and technologies to as many patients as possible and further our goal of revolutionizing precision medicine, said David D. Halbert, Chairman, Founder and CEO of Caris. We plan to unlock the full potential of precision medicine by comprehensively interrogating cancer at the molecular level and enabling the delivery of transformative applications of molecular science.We are pleased to continue our relationship with Caris, and we believe Caris is well-positioned as a precision medicine leader in this dynamic sector, said Narendra Nayak, Braidwell Partner. Caris has continued to advance its position among physicians, patients and biopharma partners as a trusted provider, molecular science leader and innovator.After receiving FDA approval, Caris recently launched MI Cancer Seek\xae, the first and only simultaneous Whole Exome and Whole Transcriptome Sequencing-based assay with FDA-approved CDx indications for molecular profiling of solid tumors for adult and pediatric patients. This minimally invasive, blood-based assay utilizes a novel circulating Nucleic Acid Sequencing (cNAS) approach with Whole Exome and Whole Transcriptome Sequencing to analyze cell-free DNA and RNA from plasma, as well as genomic DNA and messenger RNA from circulating white blood cells to distinguish somatic tumor, incidental clonal hematopoiesis and incidental germline variants.Caris Life Sciences\xae (Caris) is a leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. To learn more, please visit CarisLifeSciences.com.Download PDF: Caris Life Sciences Raises $168 Million in Private Capital from Leading Investors to Continue Platform Expansion